Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
Abstract Enzalutamide, apalutamide, and darolutamide are currently recommended for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC), but cross‐resistance of androgen receptor‐axis‐targeted therapies (ARAT) occurs. Because darolutamide has a distinct chemical structure to ot...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5189 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846157637142446080 |
|---|---|
| author | Saizo Fujmoto Kazutoshi Fujita Mitsuhisa Nishimoto Mamoru Hamaguchi Ken Kuwahara Mamoru Hashimoto Shogo Adomi Takafumi Minami Masahiro Nozawa Kazuhiro Yoshimura Hirotsugu Uemura |
| author_facet | Saizo Fujmoto Kazutoshi Fujita Mitsuhisa Nishimoto Mamoru Hamaguchi Ken Kuwahara Mamoru Hashimoto Shogo Adomi Takafumi Minami Masahiro Nozawa Kazuhiro Yoshimura Hirotsugu Uemura |
| author_sort | Saizo Fujmoto |
| collection | DOAJ |
| description | Abstract Enzalutamide, apalutamide, and darolutamide are currently recommended for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC), but cross‐resistance of androgen receptor‐axis‐targeted therapies (ARAT) occurs. Because darolutamide has a distinct chemical structure to other non‐steroidal antiandrogens, it may be effective for nmCRPC patients resistant to enzalutamide or apalutamide. We retrospectively evaluated the efficacy of switching to darolutamide in patients with nmCRPC. We included nine nmCRPC patients who experienced biochemical progression on enzalutamide or apalutamide and were switched over to darolutamide. Five patients (55.5%) had a PSA response >50% decline after starting darolutamide, with an average of 73% PSA decline. Median progression‐free survival was 6 months. In conclusion, an ARAT switch from enzalutamide or apalutamide to darolutamide might be effective for nmCRPC. Although the validation in a large‐scale cohort is necessary, the switch to darolutamide could be a promising therapeutic option after the progression of 1st line ARAT in nmCRPC patients. |
| format | Article |
| id | doaj-art-f9ff1f67dce24f7fabefde0baaee780d |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-f9ff1f67dce24f7fabefde0baaee780d2024-11-25T07:56:32ZengWileyCancer Medicine2045-76342023-02-011233176317910.1002/cam4.5189Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamideSaizo Fujmoto0Kazutoshi Fujita1Mitsuhisa Nishimoto2Mamoru Hamaguchi3Ken Kuwahara4Mamoru Hashimoto5Shogo Adomi6Takafumi Minami7Masahiro Nozawa8Kazuhiro Yoshimura9Hirotsugu Uemura10Department of Urology Kindai University Faculty of Medicine Osakasayama Osaka JapanDepartment of Urology Kindai University Faculty of Medicine Osakasayama Osaka JapanDepartment of Urology Kindai University Faculty of Medicine Osakasayama Osaka JapanDepartment of Urology, Mimihara General Hospital, Sakai Osaka JapanDepartment of Urology Kindai University Faculty of Medicine Osakasayama Osaka JapanDepartment of Urology Kindai University Faculty of Medicine Osakasayama Osaka JapanDepartment of Urology Kindai University Faculty of Medicine Osakasayama Osaka JapanDepartment of Urology Kindai University Faculty of Medicine Osakasayama Osaka JapanDepartment of Urology Kindai University Faculty of Medicine Osakasayama Osaka JapanDepartment of Urology Kindai University Faculty of Medicine Osakasayama Osaka JapanDepartment of Urology Kindai University Faculty of Medicine Osakasayama Osaka JapanAbstract Enzalutamide, apalutamide, and darolutamide are currently recommended for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC), but cross‐resistance of androgen receptor‐axis‐targeted therapies (ARAT) occurs. Because darolutamide has a distinct chemical structure to other non‐steroidal antiandrogens, it may be effective for nmCRPC patients resistant to enzalutamide or apalutamide. We retrospectively evaluated the efficacy of switching to darolutamide in patients with nmCRPC. We included nine nmCRPC patients who experienced biochemical progression on enzalutamide or apalutamide and were switched over to darolutamide. Five patients (55.5%) had a PSA response >50% decline after starting darolutamide, with an average of 73% PSA decline. Median progression‐free survival was 6 months. In conclusion, an ARAT switch from enzalutamide or apalutamide to darolutamide might be effective for nmCRPC. Although the validation in a large‐scale cohort is necessary, the switch to darolutamide could be a promising therapeutic option after the progression of 1st line ARAT in nmCRPC patients.https://doi.org/10.1002/cam4.5189apalutamideARATdarolutamideenzalutamidenmCRPCprostate cancer |
| spellingShingle | Saizo Fujmoto Kazutoshi Fujita Mitsuhisa Nishimoto Mamoru Hamaguchi Ken Kuwahara Mamoru Hashimoto Shogo Adomi Takafumi Minami Masahiro Nozawa Kazuhiro Yoshimura Hirotsugu Uemura Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide Cancer Medicine apalutamide ARAT darolutamide enzalutamide nmCRPC prostate cancer |
| title | Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide |
| title_full | Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide |
| title_fullStr | Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide |
| title_full_unstemmed | Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide |
| title_short | Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide |
| title_sort | sequential therapy with darolutamide in patients with non metastatic castration resistant prostate cancer resistant to enzalutamide or apalutamide |
| topic | apalutamide ARAT darolutamide enzalutamide nmCRPC prostate cancer |
| url | https://doi.org/10.1002/cam4.5189 |
| work_keys_str_mv | AT saizofujmoto sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide AT kazutoshifujita sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide AT mitsuhisanishimoto sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide AT mamoruhamaguchi sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide AT kenkuwahara sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide AT mamoruhashimoto sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide AT shogoadomi sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide AT takafumiminami sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide AT masahironozawa sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide AT kazuhiroyoshimura sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide AT hirotsuguuemura sequentialtherapywithdarolutamideinpatientswithnonmetastaticcastrationresistantprostatecancerresistanttoenzalutamideorapalutamide |